Clinical Trial Update: Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lumacaftor/ivacaftor in cystic fibrosis patients with the A455E CFTR mutation; study completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Lumacaftor/Ivacaftor

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2018-10-02